Esther Shohami Selected Research

Closed Head Injuries

1/2021	Chemokine Receptors CC Chemokine Receptor 5 and C-X-C Motif Chemokine Receptor 4 Are New Therapeutic Targets for Brain Recovery after Traumatic Brain Injury.
1/2021	Pharmacological blockers of CCR5 and CXCR4 improve recovery after traumatic brain injury.
1/2020	Cognitive Effects of Astaxanthin Pretreatment on Recovery From Traumatic Brain Injury.
1/2019	Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury.
5/2016	Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury?
12/2014	Ouabain improves functional recovery following traumatic brain injury.
7/2014	Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury.
3/2014	Inosine improves functional recovery after experimental traumatic brain injury.
8/2011	N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis.
5/2011	Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esther Shohami Research Topics

Disease

49	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2021 - 08/2002
29	Closed Head Injuries 01/2021 - 02/2002
16	Wounds and Injuries (Trauma) 01/2018 - 06/2002
11	Brain Injuries (Brain Injury) 12/2018 - 02/2002
7	Inflammation (Inflammations) 01/2021 - 06/2002
6	Neuroinflammatory Diseases 01/2019 - 08/2002
6	Infarction (Infarctions) 01/2019 - 04/2002
6	Craniocerebral Trauma (Head Injury) 03/2012 - 02/2002
5	Stroke (Strokes) 12/2018 - 01/2014
4	Hypoxia (Hypoxemia) 01/2015 - 11/2005
4	Brain Ischemia (Cerebral Ischemia) 01/2014 - 04/2002
3	Nervous System Diseases (Neurological Disorders) 02/2018 - 05/2010
3	Ischemia 09/2016 - 04/2002
2	Neoplasms (Cancer) 01/2021 - 02/2018
2	Gliosis 01/2021 - 12/2008
2	Edema (Dropsy) 01/2019 - 04/2013
2	Hypothermia 04/2013 - 12/2007
2	Alzheimer Disease (Alzheimer's Disease) 04/2008 - 02/2002
2	Multiple Sclerosis 04/2006 - 06/2003
2	Brain Edema (Cerebral Edema) 04/2005 - 08/2002
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2005 - 04/2002
2	Necrosis 04/2002 - 02/2002
1	Cognitive Dysfunction 12/2018
1	Memory Disorders (Memory Loss) 09/2016

Drug/Important Bio-Agent (IBA)

8	CytokinesIBA 01/2021 - 06/2002
8	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2018 - 06/2003
8	Neuroprotective AgentsIBA 01/2018 - 02/2002
8	Proteins (Proteins, Gene)FDA Link 03/2014 - 02/2002
7	EndocannabinoidsIBA 01/2019 - 02/2002
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 08/2002
6	N-Methylaspartate (NMDA)IBA 01/2018 - 04/2004
5	Glutamic Acid (Glutamate)FDA Link 01/2018 - 06/2003
4	Serine (L-Serine)FDA Link 12/2018 - 06/2015
4	Messenger RNA (mRNA)IBA 05/2006 - 03/2003
4	Peptides (Polypeptides)IBA 08/2005 - 02/2002
3	Cycloserine (Seromycin)FDA Link 09/2016 - 07/2007
3	Glycerol (Glycerine)FDA LinkGeneric 05/2016 - 02/2002
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 08/2014 - 12/2008
3	AntioxidantsIBA 03/2005 - 06/2002
2	LigandsIBA 01/2021 - 12/2018
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 12/2018 - 01/2014
2	EndotoxinsIBA 09/2016 - 07/2011
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 08/2014 - 07/2014
2	N-arachidonoyl L-serineIBA 08/2013 - 08/2011
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2013 - 05/2010
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 03/2012 - 07/2008
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2012 - 03/2005
2	Histones (Histone)IBA 05/2011 - 12/2009
2	givinostat hydrochlorideIBA 05/2011 - 12/2009
2	Histone Deacetylase InhibitorsIBA 05/2011 - 12/2009
2	Transcription Factors (Transcription Factor)IBA 02/2008 - 01/2004
2	Erythropoietin Receptors (Erythropoietin Receptor)IBA 02/2008 - 11/2005
2	Erythropoietin FDA Link 02/2008 - 11/2005
2	farnesylthiosalicylic acidIBA 08/2007 - 06/2003
2	Guanosine Triphosphate (GTP)IBA 08/2007 - 06/2003
2	ras ProteinsIBA 08/2007 - 06/2003
2	NF-kappa B (NF-kB)IBA 04/2006 - 01/2004
2	CannabinoidsIBA 01/2006 - 02/2002
2	Beclin-1IBA 01/2006 - 07/2005
2	Interleukin-18 (Interleukin 18)IBA 07/2004 - 08/2002
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2004 - 02/2002
2	Interleukin-1 (Interleukin 1)IBA 08/2002 - 08/2002
1	Maraviroc FDA Link 01/2021
1	CCR ReceptorsIBA 01/2021
1	plerixafor FDA Link 01/2021
1	fluorescent protein 583IBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	Chemokine ReceptorsIBA 01/2021
1	Carotenoids (Carotene)IBA 01/2020
1	astaxanthine (astaxanthin)IBA 01/2020
1	HU-910IBA 01/2019
1	CB2 Cannabinoid ReceptorIBA 01/2019
1	LipopolysaccharidesIBA 12/2018
1	DisintegrinsIBA 01/2018
1	Neutralizing AntibodiesIBA 01/2018
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 01/2018
1	Nerve Growth Factor (NGF)IBA 01/2018
1	staurosporine aglycone (K252a)IBA 01/2018
1	AMPA Receptors (AMPA Receptor)IBA 01/2015
1	AngiotensinsIBA 01/2015
1	Ouabain (G Strophanthin)IBA 12/2014
1	SteroidsIBA 12/2014
1	AntibodiesIBA 08/2014
1	CGP 42112AIBA 07/2014
1	Purine NucleosidesIBA 03/2014
1	Inosine FDA Link 03/2014
1	Aspartic Acid (Aspartate)FDA Link 01/2014
1	Aquaporin 4IBA 04/2013
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 04/2013
1	Hypoxia-Inducible Factor 1IBA 04/2013
1	CateninsIBA 01/2013
1	carvacrolIBA 12/2012
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 05/2012
1	incensole acetateIBA 03/2012
1	Pharmaceutical PreparationsIBA 01/2012

Therapy/Procedure

6	Therapeutics 01/2018 - 04/2007
3	Transplantation 02/2018 - 08/2014
2	Semiconductor Lasers 01/2012 - 04/2007
1	Immunomodulation 02/2018
1	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2018